So far, many diagnostics for coronavirus disease 2019 (COVID-19) have been approved for emergency use, and more are being developed daily. Based mostly on four separate methods, these tests One of the most commonly used testing methods for COVID-19, reverse transcription polymerase chain reaction (RT-PCR). With lateral flow, findings can be obtained in as little as 15 minutes, and ELISAs can be read and interpreted in less than an hour.
COVID-19 patients can be diagnosed and treated using a variety of molecular approaches, from central laboratory testing to point-of-care testing. Researchers and doctors with a background in deoxyribonucleic acid (DNA) amplification as well as antibody and antigen testing are familiar with these approaches, although they may be less familiar to the general population.
Alercell, based in Bozeman, Montana, is a biotechnology company that has made significant strides in testing for the virus. Alercell was formed in 2020 by a group of medical researchers with substantial experience in stem cell research, with the sole objective of developing, manufacturing, and distributing an effective medication for the COVID-19 pandemic. Alercell intends to offer a broad spectrum of healthcare therapies for infectious diseases as a result of this expansion. Alercell is also very active in preventative medicine. The CEO and the CMO of the company Dr. Alexandre Scheer MD are pursuing new medication and new testing method using genetic research. Scheer believes that through genetic research we have the key to enhance early diagnostic and eventually detection prior to grave illnesses enter the body. Alercell is announcing the launch of a new Leukaemia RUO test in the United States. This test is targeting Leukaemia and can check up to 55 fusion genes allowing for diagnostic classification, disease prognosis classification, and assist in the formulation of precise treatment plans. According to Scheer it is” The most comprehensive quantitative detection reagents, providing precise detection solutions for treatment”. In using such methods, the health system could end up saving significant amount of money and patients could be well treated long in advance to the painful chemotherapy treatments. Scheer is very sensitive to this topic as he himself fighting a grave cancer and is going thru the motion of all these difficult treatments. “I want to give people the opportunity to know long in advance to avoid what I am going through”, said Frederic Scheer Alercell CEO.
Frederic Scheer, co-founder of Alercell, Inc., is a former investment banker/biotechnologist with a track record of successfully listing numerous start-up firms on the Bulletin-Board and the NASDAQ in previous jobs. He has spent the last 25 years in the chemical and alternative technology businesses. Scheer possesses fifteen patents in the United States in the fields of biotechnology and nanotechnology. He started two biotechnology firms that were both publicly traded on the NASDAQ. Scheer is a graduate of the University of Paris and the Institut d’Etudes Politiques de Paris, where he earned two doctorates in law and an MBA.
His company, Alercell manufactures, promotes, and sells a broad range of fast test antibody systems worldwide. The most frequent purchasers of these items are blood banks, commercial laboratories, clinics, physicians’ offices, and government entities. Additionally, plasma protein treatment companies are frequent purchasers.
Antigen testing are used to determine whether a person has been infected. Proteins are detected by swabbing the nose or throat of individuals (antigens). The coronavirus antigen test, which may be performed at the point of care, is intended to be more rapid and simple to give than previous tests. A breakthrough in the screening of coronavirus antigens may bring users closer to alleviating widespread testing shortages. The CDC stated that in the aftermath of the COVID-19 pandemic, antigen tests can be used in a variety of ways to determine whether an infected person is still contagious.
Alercell has demonstrated its resiliency in the fight against COVID-19. ALERCELL is providing many antigen and polymerase chain reaction (PCR) products, including Luminostics’ clip COVID fast antigen test and antigen test collection kits.
Alercell is dedicated to the research, development, distribution, and production of a novel line of in-vitro fast diagnostic test kits that specifically target the COVID-19 SARS Coronavirus. Alercell’s proprietary evolving technology enables the detection of cancer in its earliest stages, allowing for the implementation of preventative actions for optimal health outcomes.
From rapid serology tests to polymerase chain reaction (PCR) and recently developed saliva tests, Alercell’s physicians collaborate with regulators to guarantee that the products offered are compliant with domestic and international regulators.
Alercell collaborates with manufacturers, providers, and other healthcare organisations to ensure that the correct medicines and fast test diagnostics are available to the right people at the right time at the lowest possible cost. Alercell is headquartered in the United States but manufactures and stores products across Europe and Asia.
Interesting Related Article: “Impact of COVID on Microscope Industry“